EWTX

Over the past six months, Edgewise Therapeutics' stock price significantly increased by 162.69% to $40.56 as of September 30, 2026, from $15.44 on October 1, 2025, representing a 170.50% increase over the last year. In July 2026, the company completed the sale of its muscular dystrophy business to Servier for $1.55 billion in upfront cash and potential additional milestone payments, strengthening its balance sheet and allowing focus on its cardiovascular pipeline, which was viewed as a positive de-risking event. On August 6, 2026, Edgewise reported Q2 2026 earnings per share (EPS) of -$0.53, missing the consensus estimate of -$0.47, with a net loss of $57.3 million, though the negative impact was likely mitigated by the Servier deal announcement. The company also announced positive top-line data from its 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 for obstructive and non-obstructive hypertrophic cardiomyopathy. In the past three months, insiders sold more stock than they bought, totaling $1,675,529.00 in sales with no purchases, and an officer and director reduced their stake by 63%. The next earnings report is estimated for November 5, 2026.